📊 SRPT Key Takeaways
Is Sarepta Therapeutics, Inc. (SRPT) a Good Investment?
Sarepta demonstrates strong revenue growth of 17.9% YoY, but this is overshadowed by deeply negative gross margins (-1.3%), unsustainable operating losses (-$699.8M), and severe cash burn (-$307.5M FCF annually). With only $801.3M in cash reserves against annual burn of $307.5M, the company has approximately 2.6 years of runway, making the path to profitability critical and uncertain.
Why Buy Sarepta Therapeutics, Inc. Stock? SRPT Key Strengths
- Revenue growing 17.9% YoY, demonstrating market demand for products
- Solid liquidity position with current ratio of 2.32x and $801.3M in cash reserves
- Moderate leverage ratio of 0.73x providing debt flexibility for refinancing
SRPT Stock Risks: Sarepta Therapeutics, Inc. Investment Risks
- Negative gross margins of -1.3% indicate fundamental unit economics problems and unsustainable business model
- Operating losses of -$699.8M on -31.8% operating margin with no clear path to profitability
- Free cash flow burn of -$307.5M annually severely constrains financial flexibility and limits runway to ~2.6 years
- Operating cash flow negative at -$205.5M indicates business operations are destroying value
Key Metrics to Watch
- Gross margin trajectory - must turn positive to validate business model
- Operating cash flow improvement - currently -$205.5M and must approach break-even
- Cash runway and quarterly burn rate - critical for solvency assessment
- Cost of revenue reduction initiatives and product portfolio productivity
Sarepta Therapeutics, Inc. (SRPT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.32x current ratio provides a solid financial cushion.
SRPT Profit Margin, ROE & Profitability Analysis
SRPT vs Healthcare Sector: How Sarepta Therapeutics, Inc. Compares
How Sarepta Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sarepta Therapeutics, Inc. Stock Overvalued? SRPT Valuation Analysis 2026
Based on fundamental analysis, Sarepta Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sarepta Therapeutics, Inc. Balance Sheet: SRPT Debt, Cash & Liquidity
SRPT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sarepta Therapeutics, Inc.'s revenue has grown significantly by 204% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.80 indicates the company is currently unprofitable.
SRPT Revenue Growth, EPS Growth & YoY Performance
SRPT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $370.0M | $6.5M | $0.34 |
| Q2 2025 | $360.5M | $6.5M | $0.07 |
| Q1 2025 | $359.5M | $36.1M | $0.37 |
| Q3 2024 | $309.3M | $6.5M | $0.34 |
| Q2 2024 | $239.0M | $6.5M | $0.07 |
| Q1 2024 | $231.5M | $36.1M | $0.37 |
| Q3 2023 | $207.8M | -$23.9M | $-0.46 |
| Q2 2023 | $211.2M | -$23.9M | $-0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sarepta Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SRPT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sarepta Therapeutics, Inc. (CIK: 0000873303)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SRPT
What is the AI rating for SRPT?
Sarepta Therapeutics, Inc. (SRPT) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRPT's key strengths?
Claude: Revenue growing 17.9% YoY, demonstrating market demand for products. Solid liquidity position with current ratio of 2.32x and $801.3M in cash reserves.
What are the risks of investing in SRPT?
Claude: Negative gross margins of -1.3% indicate fundamental unit economics problems and unsustainable business model. Operating losses of -$699.8M on -31.8% operating margin with no clear path to profitability.
What is SRPT's revenue and growth?
Sarepta Therapeutics, Inc. reported revenue of $2.2B.
Does SRPT pay dividends?
Sarepta Therapeutics, Inc. does not currently pay dividends.
Where can I find SRPT SEC filings?
Official SEC filings for Sarepta Therapeutics, Inc. (CIK: 0000873303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRPT's EPS?
Sarepta Therapeutics, Inc. has a diluted EPS of $-7.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SRPT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sarepta Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SRPT stock overvalued or undervalued?
Valuation metrics for SRPT: ROE of -62.5% (sector avg: 15%), net margin of -32.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SRPT stock in 2026?
Our dual AI analysis gives Sarepta Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SRPT's free cash flow?
Sarepta Therapeutics, Inc.'s operating cash flow is $-205.5M, with capital expenditures of $102.0M. FCF margin is -14.0%.
How does SRPT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -32.5% (avg: 12%), ROE -62.5% (avg: 15%), current ratio 2.32 (avg: 2).